Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435389 | 0.94 | KMT2A (0.43) | L3MBTL3KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6418241 | 0.92 | KMT2A (0.45) | L3MBTL3KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL27564719 | 0.90 | ALDH1A1 (0.44) | L3MBTL3KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL28735742 | 0.90 | MCHR1 (0.41) | L3MBTL3KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4114791 | 0.90 | MCHR1 (0.41) | L3MBTL3KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL3104303 | 0.84 | L3MBTL3 (0.58) | L3MBTL3KMT2ASMN1; SMN2MEN1MCHR1 | |
| SCHEMBL5227942 | 0.84 | KMT2A (0.40) | L3MBTL3KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL19710577 | 0.83 | KDM4E (0.45) | L3MBTL3SMN1; SMN2ALDH1A1MCHR1L3MBTL1 | |
| SCHEMBL3831586 | 0.79 | DPP4 (0.43) | L3MBTL3LMNAMCHR1L3MBTL1NPY5R | |
| SCHEMBL9957463 | 0.78 | L3MBTL3 (0.40) | L3MBTL3ALDH1A1L3MBTL1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884097-B | Pyrimidine derivatives, preparation method thereof and application thereof in medicine | 浙江海正药业股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2004111003-A1 | AMIDE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | SLC6A4, HTR3C, HTR3A | L3MBTL3 2415/4885KMT2A 4176/4885SMN1; SMN2 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.